Skip To Main Content
Sharon Worcester on Muck Rack

Sharon Worcester

Verified
Birmingham
As seen in: MDedge Hematology and Oncology, Medscape, WebMD, Medscape France, Medscape Noticias Médicas, Medscape PT, Internal Medicine News, MDedge Dermatology, MdEdge ObGyn, Clinical Neurology News, MDEdge, MDedge | Cardiology News and
Medical journalist. Writer. Believer in love and hope and science. Ally. Views my own. She/Her. Latest book: The Doctor As The Patient
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sharon

Contact Sharon, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Patients With Breast Cancer Taking GLP-1s Had Better Survival

|
By Sharon Worcester Verified
| Medscape Verified
Once again, a large observational study suggests GLP-1 drugs confer an all-cause mortality benefit among patients with cancer. The study, comparing GLP-1 use vs nonuse in more than 137,000 patients with breast cancer, showed a significant 4% increase in overall survival (OS) in those taking a GLP-1 drug. Results were consistent after propensity score matching across confounders such as age, weight, comorbidities, cardiovascular history, and prior breast cancer therapies, first author Jasmine S.
Open in Who Shared Issue with article?

OPTIMA Supports Therapy De-escalation in High-Risk Breast Cancer

|
By Sharon Worcester Verified
| Medscape Verified
About two thirds of patients with high-risk ER-positive, HER2-negative early breast cancer had similar outcomes whether or not they received chemotherapy alongside endocrine therapy, suggesting many may be able to safely avoid chemotherapy, according to findings from the phase 3 OPTIMA trial.
Open in Who Shared Issue with article?

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer

|
By Sharon Worcester Verified
| Medscape Verified
The FDA has approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for adults with BCG-naive, high-risk non-muscle-invasive bladder cancer (NIMBC). Approval was based on findings from the randomized, open-label POTOMAC study of 1018 patients with high-risk NIMBC who had undergone transurethral bladder tumor resection, according to the FDA approval notice.
Open in Who Shared Issue with article?
See all 1,261 articles